including thiazide-type diuretics (encouraged
as the first-line agent), loop diuretics
(for participants with advanced chronic kidney
disease), and beta-adrenergic blockers (for those
with coronary artery disease).5,27 Chlorthalidone
was encouraged as the primary thiazide-type diuretic,
and amlodipine as the preferred calciumchannel
blocker